EUVIMEDEUVIMED entdecken
QuerschnittstudieOpen Access · CC BY 4.0

OnabotulinumtoxinA Indications and Utilization Among Older Patients with Medicare: A Cross-Sectional Analysis

Atul Patel, Bilal Chughtai, Ahunna Ukah, Nina L. Alesci, Kimberly Becker Ifantides, Grace Forde

Toxins · 01.11.2026 · 18 (11) · 474

DOI: 10.3390/toxins18110474 ↗

Kurz gefasst

Querschnittstudie in der Zeitschrift Toxins, online erschienen am 01.11.2026. Verfasst von Atul Patel und 5 weiteren Autor:innen. Die Arbeit nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AbbVie.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OnabotulinumtoxinA (onabotA) is a neurotoxin that is FDA approved to treat multiple indications. However, data regarding the burden of these indications and onabotA utilization among older adults are limited. This analysis examined the prevalence of onabotA-approved indications and the proportion of those patients treated with onabotA in adults ≥65 years of age in Medicare Fee-for-Service (FFS; 2023) and Medicare Advantage (MA; 2022). Proportions of patients diagnosed with and treated for ≥2 indications were also estimated. Among FFS enrollees, 6.1% of patients were diagnosed with ≥1 indication and 7.0% of diagnosed patients received onabotA. Urological indications (3.2%) and spasticity (2.5%) were most commonly diagnosed, and 80%), and concomitant treatment of these indications was among the lowest (~5%). Differences in diagnosis and onabotA treatment rates by age, sex, and Medicaid eligibility were observed. OnabotA treatment rates among MA enrollees were lower. Among older adults, the most commonly diagnosed onabotA-approved indications had the lowest onabotA treatment rates, suggesting a potential gap between disease burden and real-world treatment utilization.

Förderung

  • AbbVie

Zitieren

APA

Patel, A., Chughtai, B., Ukah, A., Alesci, N. L., Ifantides, K. B., & Forde, G. (2026). OnabotulinumtoxinA Indications and Utilization Among Older Patients with Medicare: A Cross-Sectional Analysis. Toxins, 18(11), 474. https://doi.org/10.3390/toxins18110474

Vancouver

Patel A, Chughtai B, Ukah A, Alesci NL, Ifantides KB, Forde G. OnabotulinumtoxinA Indications and Utilization Among Older Patients with Medicare: A Cross-Sectional Analysis. Toxins. 2026;18(11):474. doi:10.3390/toxins18110474

BibTeX
@article{Patel2026,
  author = {Patel, Atul and Chughtai, Bilal and Ukah, Ahunna and Alesci, Nina L. and Ifantides, Kimberly Becker and Forde, Grace},
  title = {OnabotulinumtoxinA Indications and Utilization Among Older Patients with Medicare: A Cross-Sectional Analysis},
  journal = {Toxins},
  year = {2026},
  volume = {18},
  number = {11},
  pages = {474},
  doi = {10.3390/toxins18110474}
}
Kostenlos starten →